| abstract |
In particular aspects, the present application discloses that polypeptides comprising a ligand-binding portion of the extracellular domain of an actibin-like kinase I (ALK1) polypeptide inhibit angiogenesis in vivo, particularly in mammals suffering from angiogenesis- And the like. In addition, the present application demonstrates that inhibitors of ALKl can be used to increase perivascular cell coverage in vascular tissue including tumors and retina. This document also identifies ligands for ALK1, demonstrates that the ligand has angiogenesis inducing activity, and describes antibodies that inhibit receptor-ligand interaction. |